Ping An Securities Research Reports suggest focusing on "Innovation", "Going Global", "Equipment Updates", and "Consumer Recovery". The "Innovation" main line: Focus on innovation and layout innovative pharmaceutical varieties with global competitiveness, as well as categories with "great potential" and "good patterns". It is recommended to pay attention to Yantai Dongcheng Biochemicals, Hunan Jiudian Pharmaceutical, Eucure Biopharmaceuticals, INNOCARE, SINO BIOPHARM, Hutchmed (China), Asymchem Laboratories, Changzhou Qianhong Biopharma, TIGERMED, Kexing Biopharm, Aopuma, Yaokang Biological, and Baodao Spectral.  The "Going Global" main line: Exploring opportunities in overseas markets may still yield medium- to long-term opportunities, it is recommended to focus on ShenZhen New Industries Biomedical Engineering, United Imaging Healthcare, Sinocare Inc., Kexing Biopharm, Jiangxi Synergy Pharmaceutical, Nanjing King-Friend Biochemical Pharmaceutical, and Chengdu Easton Biopharmaceuticals.  The "Equipment Updates" main line: Central finance and local special bonds are expected to strengthen support for the replacement of medical devices, it is recommended to pay attention to United Imaging Healthcare, Auhua Endoscopy, Sonoscape Medical Corp., and others.  The "Consumer Recovery" main line: Under the influence of consumption stimulus policies, high-quality tracks such as ophthalmology, dentistry, and medical aesthetics, as well as related peripheral industries are expected to recover, it is recommended to focus on PuRui Ophthalmology, Topchoice Medical, and Shanghai Haohai Biological Technology.